National Biocontainment Laboratories (NBLs) Operations Support Limited Competition (UC7)

The summary for the National Biocontainment Laboratories (NBLs) Operations Support Limited Competition (UC7) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	National Biocontainment Laboratories (NBLs) Operations Support Limited Competition (UC7)
	CFDA Number:	93.856
	CFDA Description:	Microbiology and Infectious Diseases Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-AI-10-018
	Document Type:	Grants Notice
	Funding Instrument Type:	Cooperative Agreement
	Posted Date:	Jun 10, 2010
	Creation Date:	Jun 10, 2010
	Original Closing Date for Applications:	Jul 13, 2010
	Current Closing Date for Applications:	Jul 13, 2010
	Archive Date:	Aug 13, 2010
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	$30,000,000
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: The University of Texas Medical Branch at Galveston, TX Boston University, Boston, MA
Grant Description: Purpose. This FOA issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, is a limited competition solicitation intended to continue operations support under the UC7 mechanism for Biosafety Level 4 (BSL4) facilities at the National Biocontainment Laboratories at the University of Texas Medical Branch (UTMB) in Galveston, Texas and Boston University in Boston, Massachusetts. Operations support is provided in the following areas: facility maintenance and operations; biosecurity; environmental health and safety regulations and requirements; regulatory compliance; and specialized research support services. The NBLs will serve as a national resource for efforts in conducting clinical and laboratory (in vitro and in vivo) research and testing on hazardous biological agents in support of NIAIDs Biodefense Research Agenda (http://www.niaid.nih.gov/topics/biodefenserelated/biodefense/about/pages/strategicplan.aspx) and other infectious diseases. Mechanism of Support. This FOA will utilize the UC7 award mechanism. Funds Available and Anticipated Number of Awards. The NIAID intends to commit up to $30 million in total costs annually in Fiscal Years 2011-2016 to fund the NBLs.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-ai-10-018.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Biomedical Prevention of HIV Research Education (R25); • Partnerships for Next Generation Biodefense Diagnostics (R01); • Partnerships for Development of New Therapeutic Classes for Select Viral and Bacterial Pathogens (R0...; • International Extramural Associates Research Development Awards (IEARDA) [G11]; • Indo-U.S. Vaccine Action Program (VAP) Small Research Grant Program (R03); • Non-Antibiotic Selectable Markers for Biodefense (R21); • Partnerships to Improve Diagnosis and Treatment of Selected Drug-Resistant Healthcare-Associated Inf...; • Cooperative Research Partnerships for Biodefense (U01); • Pharmacological Approaches to Combating Antimicrobial Resistance (R01); • Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE) [U54]